Published in Hum Genet on November 15, 2005
Chronic medical conditions and risk of sepsis. PLoS One (2012) 1.16
Heterogeneous effect of two selectin gene polymorphisms on coronary artery disease risk: a meta-analysis. PLoS One (2014) 0.86
Association Between 3 IL-10 Gene Polymorphisms and Cardiovascular Disease Risk: Systematic Review With Meta-Analysis and Trial Sequential Analysis. Medicine (Baltimore) (2016) 0.78
Association between three interleukin-10 gene polymorphisms and coronary artery disease risk: a meta-analysis. Int J Clin Exp Med (2015) 0.77
Association between the interleukin-6 genetic polymorphism 174 G/C and thrombosis disorder risk: Meta-analysis of 10,549 cases and 19,316 controls. Medicine (Baltimore) (2016) 0.75
Influence of two common polymorphisms in the EPHX1 gene on warfarin maintenance dosage: a meta-analysis. Biomed Res Int (2015) 0.75
Risk of Acute Stroke After Hospitalization for Sepsis: A Case-Crossover Study. Stroke (2017) 0.75
Interaction between air pollution exposure and genes in relation to levels of inflammatory markers and risk of myocardial infarction. BMJ Open (2013) 0.75
Inflammation and atherosclerosis. Circulation (2002) 20.77
A comparison of linkage disequilibrium measures for fine-scale mapping. Genomics (1995) 11.58
Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation (2000) 8.17
The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med (1997) 5.07
Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis (2000) 4.88
Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation (1997) 4.41
Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet (1998) 3.97
Prediction of myocardial infarction in dyslipidemic men by elevated levels of immunoglobulin classes A, E, and G, but not M. Arch Intern Med (1998) 3.01
The combined role of P- and E-selectins in atherosclerosis. J Clin Invest (1998) 2.53
The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J (2001) 2.21
Ile50Val variant of IL4R alpha upregulates IgE synthesis and associates with atopic asthma. Nat Genet (1998) 2.12
Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol (2002) 1.73
In the elderly, interleukin-6 plasma levels and the -174G>C polymorphism are associated with the development of cardiovascular disease. Arterioscler Thromb Vasc Biol (2002) 1.70
Soluble P-selectin and the risk of future cardiovascular events. Circulation (2001) 1.69
Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation (2003) 1.67
Logistic regression model for analyzing extended haplotype data. Genet Epidemiol (1998) 1.61
New polymorphisms in the interleukin-10 gene--relationships to myocardial infarction. Eur J Clin Invest (2001) 1.50
Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis. Hum Mol Genet (2003) 1.33
Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation (2000) 1.24
Association between P-selectin gene polymorphisms and soluble P-selectin levels and their relation to coronary artery disease. Arterioscler Thromb Vasc Biol (2001) 1.18
The P-selectin gene is highly polymorphic: reduced frequency of the Pro715 allele carriers in patients with myocardial infarction. Hum Mol Genet (1998) 1.15
Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS). Arterioscler Thromb Vasc Biol (2002) 1.12
Interleukin-6 gene polymorphisms and susceptibility to myocardial infarction: the ECTIM study. Etude Cas-Témoin de l'Infarctus du Myocarde. J Mol Med (Berl) (2001) 1.11
The interleukin-6 G(-174)C promoter polymorphism in the LURIC cohort: no association with plasma interleukin-6, coronary artery disease, and myocardial infarction. J Mol Med (Berl) (2002) 1.09
A novel polymorphism in the 5' promoter region of the human interleukin-4 receptor alpha-chain gene is associated with decreased soluble interleukin-4 receptor protein levels. Immunogenetics (2001) 1.07
Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils. Blood (1997) 1.01
Soluble P-selectin levels, P-selectin polymorphisms and cardiovascular disease. J Thromb Haemost (2003) 1.00
IL-4 production is increased in cigarette smokers. Clin Exp Immunol (1994) 0.96
Threonine for alanine substitution in the eotaxin (CCL11) gene and the risk of incident myocardial infarction. Atherosclerosis (2004) 0.88
Genetic influence on cigarette-induced cardiovascular disease. Prog Cardiovasc Dis (2003) 0.79
The association between inflammation markers, coronary artery disease and smoking. Vascul Pharmacol (2002) 0.78
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Inflammation and atherosclerosis. Circulation (2002) 20.77
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med (2002) 16.23
Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA (2007) 15.32
Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology (2010) 14.07
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 12.09
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA (2007) 9.68
Statins: new American guidelines for prevention of cardiovascular disease. Lancet (2013) 9.56
Progress and challenges in translating the biology of atherosclerosis. Nature (2011) 9.41
Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med (2009) 7.62
C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation (2008) 7.33
Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med (2002) 7.32
C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation (2003) 6.99
Population analysis of large copy number variants and hotspots of human genetic disease. Am J Hum Genet (2009) 6.79
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Migraine and risk of cardiovascular disease in women. JAMA (2006) 6.16
Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol (2009) 6.11
Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol (2004) 6.08
Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med (2009) 6.00
Sugar-sweetened beverages and genetic risk of obesity. N Engl J Med (2012) 5.98
Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. Am J Med (2007) 5.95
C-reactive protein and the risk of developing hypertension. JAMA (2003) 5.75
Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA (2005) 5.74
The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med (2006) 5.69
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet (2009) 4.78
Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet (2009) 4.71
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA (2004) 4.47
Association between a literature-based genetic risk score and cardiovascular events in women. JAMA (2010) 4.46
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med (2009) 4.46
Rationale, design, and methodology of the Women's Genome Health Study: a genome-wide association study of more than 25,000 initially healthy american women. Clin Chem (2007) 4.45
Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet (2008) 4.31
Inflammation as a cardiovascular risk factor. Circulation (2004) 4.26
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation (2009) 3.93
Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov (2005) 3.92
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Childhood blood pressure trends and risk factors for high blood pressure: the NHANES experience 1988-2008. Hypertension (2013) 3.81
Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet (2012) 3.71
Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation (2011) 3.68
Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. Am J Hum Genet (2008) 3.61
Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation (2012) 3.61
Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet (2011) 3.40
Thirty new loci for age at menarche identified by a meta-analysis of genome-wide association studies. Nat Genet (2010) 3.37
Relationship of physical activity vs body mass index with type 2 diabetes in women. JAMA (2004) 3.31
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25
Genetic variants at 2q24 are associated with susceptibility to type 2 diabetes. Hum Mol Genet (2010) 3.24
Blood pressure and risk of developing type 2 diabetes mellitus: the Women's Health Study. Eur Heart J (2007) 3.21
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation (2007) 3.20
Genome-wide association studies identify loci associated with age at menarche and age at natural menopause. Nat Genet (2009) 3.06
Using relative utility curves to evaluate risk prediction. J R Stat Soc Ser A Stat Soc (2009) 3.04
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet (2012) 3.04
High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation (2013) 3.03
Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation (2008) 3.03
Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation (2013) 3.02
Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr (2002) 3.00
Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA (2006) 2.99
The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study). J Am Coll Cardiol (2010) 2.96
Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care (2009) 2.96
Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med (2007) 2.95
Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med (2010) 2.94
Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation (2006) 2.93
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: periodontitis and atherosclerotic cardiovascular disease. Am J Cardiol (2009) 2.91
Body mass index and the risk of stroke in men. Arch Intern Med (2002) 2.90
Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care (2005) 2.89
Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women. PLoS Genet (2008) 2.85
Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation (2002) 2.84
Sex-stratified genome-wide association studies including 270,000 individuals show sexual dimorphism in genetic loci for anthropometric traits. PLoS Genet (2013) 2.83
Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation (2006) 2.81
Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol (2002) 2.79
C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med (2005) 2.79
Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation (2002) 2.78